Table 3 Correlation between loss of heterozygosity of chromosome 9p and various tumour characteristics in clinically localized renal cell carcinoma

Tumour size

Mean

5.3

4.6

0.93

4.8

6.4

0.76

4.8

6.4

0.17

4.8

6.4

0.77

5.1

5.3

0.66

SD

(±3.2)

(±2.1)

(±2.9)

(±3.4)

(±2.9)

(±3.4)

(±2.9)

(±3.4)

(±3.2)

(±2)

T stage

pT1

20

4

0.005

28

2

0.004

29

2

0.003

19

0

0.028

22

5

0.42

pT2

12

0

7

1

11

0

8

0

12

0

pT3

9

5

13

5

13

6

7

3

12

5

pT4

0

2

0

2

0

1

1

0

0

1

pT1/2

32

4

0.02

35

3

0.02

40

2

0.004

27

0

0.02

34

5

0.084

pT3/4

9

7

13

7

13

7

8

3

12

6

Metastasis

N0M0

38

8

0.1

46

6

0.006

50

5

0.006

33

2

0.224

42

8

0.12

N + M+

3

3

2

4

3

4

2

1

4

3

Fuhrman Grade

G1/G2

16

4

1

18

2

0.47

20

2

0.47

14

1

1

18

3

0.73

G3/G4

25

7

30

8

33

7

21

2

28

8

Tumour necrosis

Present

10

3

1

14

3

1

16

1

0.42

10

0

0.55

14

3

1

Absent

29

7

33

6

35

7

23

3

30

7

Sarcomatoid change

Present

1

3

0.02

2

2

0.12

4

1

0.53

4

1

0.37

3

2

0.23

Absent

38

7

45

7

47

7

29

2

41

8

Microvascular invasion

Present

10

2

1

11

3

0.68

13

3

0.67

9

1

1

12

3

1

Absent

28

8

36

6

38

5

23

2

31

7

Renal Vein invasion

Present

6

2

1

8

2

0.67

8

2

0.62

3

1

0.32

7

2

1

Absent

31

8

37

7

41

6

28

2

34

8

Pelvicalyceal invasion

Present

4

0

0.56

6

1

1

6

1

1

2

1

0.25

7

0

0.32

Absent

33

10

39

8

43

7

29

2

34

10

Renal sinus invasion

Present

3

4

0.03

5

4

0.03

5

4

0.016

3

2

0.068

5

4

0.06

Absent

34

6

40

5

44

4

23

1

36

6

SSIGN score

0–2

17

5

0.16

21

3

0.26

22

2

0.29

16

1

0.011

17

4

0.43

S – Stage

03–Apr

4

0

7

0

6

1

4

0

4

0

SI – Size

05–Jun

11

1

9

2

11

2

3

1

10

3

G – Grade

07–Sep

4

2

6

2

8

1

8

0

8

1

N - Necrosis

≥10

1

2

2

2

2

2

0

1

2

2